Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043225 | 0.89 | HTT (0.61) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL3078708 | 0.89 | MAPT (0.65) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL2772330 | 0.89 | MAPT (0.61) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL3080754 | 0.88 | MAPT (0.61) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL14975682 | 0.88 | TSHR (0.50) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL9390762 | 0.88 | TSHR (0.58) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL2847294 | 0.87 | TDP1 (0.64) | HTTMAPTHSP90AA1NPSR1ALDH1A1 | |
| SCHEMBL6042705 | 0.87 | MAPT (0.59) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL16482859 | 0.86 | MAOA (0.54) | HTTMAPTHSP90AA1NPSR1L3MBTL1 | |
| SCHEMBL14974837 | 0.85 | TSHR (0.50) | HTTMAPTHSP90AA1NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078922-B2 | Metal-organic frameworks with exceptionally large pore aperatures | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130096210-A1 | METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-18 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | HTT 4430/4885MAPT 3995/4885HSP90AA1 969/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | HTT 4189/4885MAPT 4429/4885HSP90AA1 698/4885 |
| US-20130096210-A1 | METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES | AP3M1, AP2M1, AP2A2 | HTT 3798/4885MAPT 3548/4885HSP90AA1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.